Premium
Intravenous urethane (ethyl carbamate) therapy of multiple myeloma. From the acute leukemia group B
Author(s) -
Seibert Dean J.,
Hayes Donald M.,
Cooper Talbert,
Blom Johannes,
Ebaugh Franklin G.
Publication year - 1966
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(196605)19:5<710::aid-cncr2820190517>3.0.co;2-9
Subject(s) - medicine , toxicity , multiple myeloma , carbamate , body weight , gastroenterology , anesthesia , surgery , organic chemistry , chemistry
Urethane (ethyl carbamate) was administered intravenously to 30 patients in repeated doses of 0.2 Gm/kg body weight 3 times weekly every other week unless prohibitive toxicity occurred. The total duration of therapy ranged between one and 207 days and the total dose administered ranged between 20 and 280 Gm. Objective improvement occurred in 5 of 30 patients (16%). Subjective improvement occurred in 7 of 30 patients (23%). It is concluded that the usefulness of intravenous urethane is limited since objective improvement never occurred in more than one disease parameter despite significant hematopoietic toxicity.